B Pardo-Galiana1,2, M Medina-Rodriguez1,2, M Millan-Vazquez3, J A Cabezas-Rodriguez1,2, L Lebrato-Hernandez1,2, L Ainz-Gomez1,2, E Zapata-Arriaza4,2, J Ortega4,2, A de Albóniga-Chindurza4,2, J Montaner2,5, A Gonzalez4,2, F Moniche6,2. 1. From the Stroke Unit (B.P.-G., M.M.-R., J.A.C.-R., L.L.-H., L.A.-G., F.M.). 2. Neurovascular Lab (B.P.-G., M.M.-R., J.A.C.-R., L.L.-H., L.A.-G., E.Z.-A., J.O., A.d.A.-C., J.M., A.G., F.M.), Biomedicine Institute of Seville, Seville, Spain. 3. Neurology Department (M.M.-V.). 4. Interventional Neuroradiology Unit (E.Z.-A., J.O., A.d.A.-C., A.G.), Radiology Department, University Hospital Virgen del Rocio, Seville, Spain. 5. Stroke Unit (J.M.), Neurology Department, University Hospital Virgen Macarena, Seville, Spain. 6. From the Stroke Unit (B.P.-G., M.M.-R., J.A.C.-R., L.L.-H., L.A.-G., F.M.) pmoniche@gmail.com.
Abstract
BACKGROUND AND PURPOSE: Antithrombotic therapy following carotid artery stent placement with concomitant atrial fibrillation is not well-established. Our aim was to assess the safety and efficacy of the combination of direct oral anticoagulants and a P2Y12 inhibitor at 30 days after carotid artery stent placement in patients with atrial fibrillation. MATERIALS AND METHODS: We designed an observational single-center study including patients who underwent carotid artery stent placement with concomitant atrial fibrillation. We studied 3 groups according to antithrombotic therapy: 1) the direct oral anticoagulants plus clopidogrel (DC) group: receiving direct oral anticoagulants plus a P2Y12 inhibitor; 2) the triple therapy group: anticoagulation and dual antiplatelet therapy; and 3) the dual antiplatelet therapy group: following dual antiplatelet therapy alone. The safety outcome was a major or clinically relevant non-major bleeding event at the first month. The efficacy outcomes were the thromboembolic events (myocardial infarction, stroke, systemic embolism, or stent thrombosis). RESULTS: Of 959 patients with carotid artery stent placement, 91 met the inclusion criteria, including 24 patients in the DC group, 42 patients in the triple therapy group, and 25 in the dual antiplatelet therapy group. The mean age was 72.27 (SD, 8.1 ) years, with similar baseline characteristics. The median CHA2DS2-VASc score for each group was 6 (interquartile range = 5-6), 5 (interquartile range = 4-6), and 5 (interquartile range = 4-6), respectively. The median HAS-BLED score was 4 in the 3 groups (P = .17). The primary safety end point was 23.8% in the triple therapy group compared with 4% in the dual antiplatelet therapy group (P = .032), with no bleeding events in the DC group (P = .007). There was 1 stent thrombosis in DC group and a cardioembolic stroke in the dual antiplatelet therapy group (P = .41). CONCLUSIONS: Among patients with carotid artery stent placement with atrial fibrillation, triple therapy confers a high bleeding risk. A regimen of direct oral anticoagulants plus a P2Y12 inhibitor might confer a good safety profile with significantly lower rates of bleeding and optimal efficacy.
BACKGROUND AND PURPOSE: Antithrombotic therapy following carotid artery stent placement with concomitant atrial fibrillation is not well-established. Our aim was to assess the safety and efficacy of the combination of direct oral anticoagulants and a P2Y12 inhibitor at 30 days after carotid artery stent placement in patients with atrial fibrillation. MATERIALS AND METHODS: We designed an observational single-center study including patients who underwent carotid artery stent placement with concomitant atrial fibrillation. We studied 3 groups according to antithrombotic therapy: 1) the direct oral anticoagulants plus clopidogrel (DC) group: receiving direct oral anticoagulants plus a P2Y12 inhibitor; 2) the triple therapy group: anticoagulation and dual antiplatelet therapy; and 3) the dual antiplatelet therapy group: following dual antiplatelet therapy alone. The safety outcome was a major or clinically relevant non-major bleeding event at the first month. The efficacy outcomes were the thromboembolic events (myocardial infarction, stroke, systemic embolism, or stent thrombosis). RESULTS: Of 959 patients with carotid artery stent placement, 91 met the inclusion criteria, including 24 patients in the DC group, 42 patients in the triple therapy group, and 25 in the dual antiplatelet therapy group. The mean age was 72.27 (SD, 8.1 ) years, with similar baseline characteristics. The median CHA2DS2-VASc score for each group was 6 (interquartile range = 5-6), 5 (interquartile range = 4-6), and 5 (interquartile range = 4-6), respectively. The median HAS-BLED score was 4 in the 3 groups (P = .17). The primary safety end point was 23.8% in the triple therapy group compared with 4% in the dual antiplatelet therapy group (P = .032), with no bleeding events in the DC group (P = .007). There was 1 stent thrombosis in DC group and a cardioembolic stroke in the dual antiplatelet therapy group (P = .41). CONCLUSIONS: Among patients with carotid artery stent placement with atrial fibrillation, triple therapy confers a high bleeding risk. A regimen of direct oral anticoagulants plus a P2Y12 inhibitor might confer a good safety profile with significantly lower rates of bleeding and optimal efficacy.
Authors: H Lehtola; K E J Airaksinen; P Hartikainen; J E K Hartikainen; A Palomäki; I Nuotio; A Ylitalo; T Kiviniemi; P Mustonen Journal: Eur J Neurol Date: 2017-03-20 Impact factor: 6.089
Authors: Renato D Lopes; Gretchen Heizer; Ronald Aronson; Amit N Vora; Tyler Massaro; Roxana Mehran; Shaun G Goodman; Stephan Windecker; Harald Darius; Jia Li; Oleg Averkov; M Cecilia Bahit; Otavio Berwanger; Andrzej Budaj; Ziad Hijazi; Alexander Parkhomenko; Peter Sinnaeve; Robert F Storey; Holger Thiele; Dragos Vinereanu; Christopher B Granger; John H Alexander Journal: N Engl J Med Date: 2019-03-17 Impact factor: 91.245
Authors: Jean Jacques Noubiap; Thomas A Agbaedeng; Joel Noutakdie Tochie; Jan René Nkeck; Aude Laetitia Ndoadoumgue; John L Fitzgerald; Timothy Kleinig; Gijo Thomas; Melissa E Middeldorp; Prashanthan Sanders Journal: Am J Cardiol Date: 2020-10-13 Impact factor: 2.778
Authors: Christopher P Cannon; Deepak L Bhatt; Jonas Oldgren; Gregory Y H Lip; Stephen G Ellis; Takeshi Kimura; Michael Maeng; Bela Merkely; Uwe Zeymer; Savion Gropper; Matias Nordaby; Eva Kleine; Ruth Harper; Jenny Manassie; James L Januzzi; Jurrien M Ten Berg; P Gabriel Steg; Stefan H Hohnloser Journal: N Engl J Med Date: 2017-08-27 Impact factor: 91.245
Authors: Tyler S Cole; Andrew W Mezher; Joshua S Catapano; Jakub Godzik; Jacob F Baranoski; Peter Nakaji; Felipe C Albuquerque; Michael T Lawton; Andrew S Little; Andrew F Ducruet Journal: Stroke Date: 2019-12-18 Impact factor: 7.914
Authors: C Michael Gibson; Roxana Mehran; Christoph Bode; Jonathan Halperin; Freek W Verheugt; Peter Wildgoose; Mary Birmingham; Juliana Ianus; Paul Burton; Martin van Eickels; Serge Korjian; Yazan Daaboul; Gregory Y H Lip; Marc Cohen; Steen Husted; Eric D Peterson; Keith A Fox Journal: N Engl J Med Date: 2016-11-14 Impact factor: 91.245
Authors: Eric S Sussman; Michael Jin; Arjun V Pendharkar; Benjamin Pulli; Austin Feng; Jeremy J Heit; Nicholas A Telischak Journal: J Neurointerv Surg Date: 2020-05-15 Impact factor: 5.836
Authors: Johannes M Weller; Franziska Dorn; Julius N Meissner; Sebastian Stösser; Niklas M Beckonert; Julia Nordsiek; Christine Kindler; Christoph Riegler; Fee Keil; Gabor C Petzold; Felix J Bode Journal: Neurol Res Pract Date: 2022-09-12